Categories: News

Invitation to presentation of RaySearch’s interim report for the third quarter of 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

STOCKHOLM, Oct. 21, 2024 /PRNewswire/ — Analysts, investors, and the media are invited to a presentation of RaySearch’s interim report for the third quarter of 2024 on November 8, 2024, at 10.00 am CET. The report will be published on November 8, 2024, at 07.45 am and will be available together with presentation slides on raysearchlabs.com. Johan Löf, founder and CEO, and Annika Blondeau Henriksson, interim CFO, will present the company’s development in a webcast. After the presentation (held in English) there is the opportunity to ask questions.

Link to webcast: RaySearch Q3, 2024

For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/raysearch-laboratories/r/invitation-to-presentation-of-raysearch-s-interim-report-for-the-third-quarter-of-2024,c4053756

The following files are available for download:

https://mb.cision.com/Main/1102/4053756/3063388.pdf

RaySearch Press Release October 21, 2024

 

View original content:https://www.prnewswire.com/news-releases/invitation-to-presentation-of-raysearchs-interim-report-for-the-third-quarter-of-2024-302281487.html

SOURCE RaySearch Laboratories

Staff

Recent Posts

Epic UGM 2025 Survival Guide: Insider Tips for Vendors, Storytellers, and Market Watchers

Black Book Research Marks Its 12th Year on the Ground in Verona with Independent, Vendor-Agnostic…

15 hours ago

rYojbaba Co., Ltd. Announces Closing of $5 Million Initial Public Offering of Japanese Common Shares

FUKUOKA, Japan, Aug. 15, 2025 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (Nasdaq: RYOJ) (“rYojbaba” or…

18 hours ago

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug…

18 hours ago

BioSig Technologies, Inc. & Streamex Announce Closing of $15 Million Public Offering

Offering Structured to Accelerate Streamex’s Operational Build-Out, Strategically Allocated with No WarrantsLos Angeles, CA, Aug.…

18 hours ago

Jabez Biosciences, Inc. Opens Second Clinical Site in Phase 1 Oncology Clinical Study of JBZ-001

CRANBERRY TOWNSHIP, Pa., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Jabez Biosciences, Inc., a clinical-stage biopharmaceutical…

18 hours ago